CD19 and neoplasm: Moreover, when CCR7 CD19 t-haNK cells injected into NSG mice inoculated with CCL19-secreting Raji lymphoma cells, tumor control and survival were increased in both local and systemic tumor models compared to mice treated with CD19 t-haNK cells that do not express the CCR7 receptor and control mice.